The fortnight ending 10 October 2021 appears to be the last fortnight where JobSaver payments amount to 40% of weekly payroll or $1,000/week for non-employing businesses. From then, JobSaver payments reduce to 30% of weekly payroll or $750/week for non-employing businesses until the 80% vaccination double dose target is met. From that point, JobSaver payments reduce to 15% of weekly payroll or $375/week for non-employing businesses until the scheme ends. The minimum and maximum weekly payments for employing businesses also reduce at the two critical dates.
Details of the JobSaver tapering are set out below:
JobSaver (excluding extension program) | Share of weekly payroll | Weekly payment range (paid fortnightly) | Weekly payments to non-employing business (paid fortnightly) |
Current | 40% | $1,500 to $100,000 | $1,000 |
10 October 2021 | 30% | $1,125 to $75,000 | $750 |
80% double dose | 15% | $562.50 to $37,500 | $375 |
30 November 2021 | | No further payments | No further payments |
Based on current vaccination rates, it appears that the period during which JobSaver payments will be 30% of weekly payroll or $750/week for non-employing businesses will be just one fortnight.
Should you have any questions, please contact your usual Mazars advisor, the author, or if you require assistance with claims or want to know more, please contact your local office below.
Author: Stephen Baxter
Brisbane | Melbourne | Sydney |
+61 7 3218 3900 | +61 3 9252 0800 | +61 2 9922 1166 |
Published: 11/10/2021
All rights reserved. This publication in whole or in part may not be reproduced, distributed or used in any manner whatsoever without the express prior and written consent of the Mazars, except for the use of brief quotations in the press, in social media or in another communication tool, as long as Mazars and the source of the publication are duly mentioned. In all cases, Mazars’ intellectual property rights are protected and the Mazars Group shall not be liable for any use of this publication by third parties, either with or without Mazars’ prior authorisation. Also please note that this publication is intended to provide a general summary and should not be relied upon as a substitute for personal advice. Content is accurate as at the date published.